Agency officials promise fast reviews of new treatments while vowing they will not be a “rubber stamp” for the industry. But patients with rare diseases view recent decisions as signs that the doors are closing on their options.
Previous Story
James Talarico Says ‘New Politics Is Being Born’ After Texas Primary Win
Next Story
The Long March of Presidential Power That Led to War on Iran
